



Chemours 1Q 2022 Earnings Presentation

May 2, 2022



Safe Harbor Statement and Other Matters

This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to a historical or current fact. The words "believe," "expect," "will," "anticipate," "plan," "estimate," "target," "project" and similar expressions, among others, generally identify "forward-looking statements," which speak only as of the date such statements were made. These forward-looking statements may address, among other things, the outcome or resolution of any pending or future environmental liabilities, the commencement, outcome or resolution of any regulatory inquiry, investigation or proceeding, the initiation, outcome or settlement of any litigation, changes in environmental regulations in the U.S. or other jurisdictions that affect demand for or adoption of our products, anticipated future operating and financial performance for our segments individually and our company as a whole, business plans, prospects, targets, goals and commitments, capital investments and projects and target capital expenditures, plans for dividends or share repurchases, sufficiency or longevity of intellectual property protection, cost reductions or savings targets, plans to increase profitability and growth, our ability to make acquisitions, integrate acquired businesses or assets into our operations, and achieve anticipated synergies or cost savings, all of which are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized. These statements are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond Chemours' control. In addition, the current COVID-19 pandemic has significantly impacted the national and global economy and commodity and financial markets, which has had and we expect will continue to have a negative impact on our financial results. The full extent and impact of the pandemic is still being determined and to date has included significant volatility in financial and commodity markets and a severe disruption in economic activity. The public and private sector response has led to travel restrictions, temporary business closures, quarantines, stock market volatility, and interruptions in consumer and commercial activity globally. Matters outside our control have affected our business and operations and may or may continue to hinder our ability to provide goods and services to customers, cause disruptions in our supply chains, adversely affect our business partners, significantly reduce the demand for our products, adversely affect the health and welfare of our personnel or cause other unpredictable events. Additionally, there may be other risks and uncertainties that Chemours is unable to identify at this time or that Chemours does not currently expect to have a material impact on its business. Factors that could cause or contribute to these differences include the risks, uncertainties and other factors discussed in our filings with the U.S. Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2021. Chemours assumes no obligation to revise or update any forward-looking statement for any reason, except as required by law.

We prepare our financial statements in accordance with Generally Accepted Accounting Principles ("GAAP"). Within this presentation we may make reference to Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow, Adjusted Effective Tax Rate, Return on Invested Capital (ROIC) and Net Leverage Ratio which are non-GAAP financial measures. The company includes these non-GAAP financial measures because management believes they are useful to investors in that they provide for greater transparency with respect to supplemental information used by management in its financial and operational decision making. Further information with respect to and reconciliations of such measures to the nearest GAAP measure can be found in the appendix hereto.

Management uses Adjusted Net Income, Adjusted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow, Adjusted Effective Tax Rate, ROIC and Net Leverage Ratio to evaluate the company's performance excluding the impact of certain noncash charges and other special items which we expect to be infrequent in occurrence in order to have comparable financial results to analyze changes in our underlying business from quarter to quarter.

Additional information for investors is available on the company's website at investors.chemours.com.

First Quarter 2022 Highlights

Delivered strong 1Q results with Net Sales growth of 23% and Adjusted EBITDA growth of 50%

Achieved exceptional results in TSS & APM, led by strong price, volume and mix enrichment

Managing through prolonged ore constraints in TT, now expected to continue into 2H

Completed \$146 million of share repurchases; plan to complete 2018 authorization in 1H

Raised 2022 FY Adjusted EBITDA guidance by 12% at the mid-point, and FCF by \$50 million

First Quarter 2022 Financial Summary

(\$ in millions unless otherwise noted)

	1Q22	1Q21	Δ Yr/Yr
Net Sales	\$1,764	\$1,436	\$328
Net Income ¹	\$234	\$96	\$138
Adj. Net Income	\$239	\$120	\$119
EPS ²	\$1.43	\$0.57	\$0.86
Adj. EPS ²	\$1.46	\$0.71	\$0.75
Adj. EBITDA	\$403	\$268	\$135
Adj. EBITDA Margin (%) ³	23%	19%	4%
Free Cash Flow ⁴	\$(104)	\$(21)	\$(83)

See reconciliation of Non-GAAP measures in the Appendix

¹ Net Income attributable to The Chemours Company

² Calculation based on diluted share count

³ Defined as Adjusted EBITDA divided by Net Sales

⁴ Defined as Cash from Operations minus cash used for PP&E purchases

⁵ Adjusted EPS excludes restructuring, gain/loss on sale, legal and environmental charges— see Appendix for full details

Year-Over-Year

- Net Sales up 23% to \$1.8 billion reflecting strength across the portfolio
- GAAP EPS of \$1.43 up \$0.86 and Adjusted EPS of \$1.46 up \$0.75 ⁵
- Adjusted EBITDA of \$403 million up 50% y-o-y, driven by higher price, volumes and improved mix
- Margins improved to 23% from 19% in the prior year quarter as price continued to stay well ahead of cost
- Free cash flow of \$(104) million driven by increased NWC consumption to support higher demand as well as a return to normalized seasonality across our businesses


Adjusted EBITDA Bridge: 1Q22 versus 1Q21

(\$ in millions unless otherwise noted)

- Price momentum driven by strong demand due to market dynamics in TSS, demand for high value applications in APM, and contractual price increases plus stronger Flex/ Distribution price in TT

- Volumes increased across product lines, partially offset by auto OEM demand headwinds and ore constraints


- Higher variable costs due to supply chain issues, logistics and raw material inflation
- Higher operating costs to support higher demand



See reconciliation of Non-GAAP measures in the Appendix

Liquidity Position

(\$ in millions unless otherwise noted)



Gross debt	\$3.7B
Net debt	\$2.6B
TTM Net Leverage	1.8x

- Q1'22 ending cash balance of \$1,145 million
- Breakeven Operating Cash Flow (~\$2 million) as strong operating earnings primarily offset by increased working capital to support high demand and seasonality
- Distributed \$184 million of cash to shareholders
- Total Liquidity of ~\$1.9 billion¹

See reconciliation of Non-GAAP measures in the Appendix

¹ Including revolver availability of ~\$0.8 billion

² Excludes \$6 million in repurchases that were executed but not settled until after Q1'22 close

³ Cash balances do not include \$100 million of restricted cash which are part of Chemours' MOU commitments

Titanium Technologies Business Summary

First Quarter Highlights


- Net Sales increased 28% to \$928 million driven by 24% contribution from price and a 6% contribution from increased volumes
- Favorable pricing the result of contractual price changes and price improvements in our Flex/Distribution channels
- Volume increases were driven by steady demand across almost all end-markets and regions; volume increase delivered despite ore constraints

Outlook

- Continued demand strength expected in all end-markets and across all geographies
- Expect demand strength to be partially offset by continued ore constraints which are now expected to persist into the second half of 2022

First Quarter 2022 Financial Summary (\$ in millions)


Quarterly Net Sales



Sales Drivers

	Yr/Yr % Δ	Q/Q % Δ
Price	24	4
Volume	6	3
Currency	(2)	0

Quarterly Adjusted EBITDA



See reconciliation of Non-GAAP measures in the Appendix. Note that, beginning in 2022, the Company changed its methodology used to allocated certain corporate function expenses to the operating segments, and as such historical Adjusted EBITDA has been recast.

Thermal & Specialized Solutions Business Summary

First Quarter Highlights


- Delivered 40% Net Sales growth driven by strong demand and robust pricing across the business, despite continued automotive OEM demand headwinds
- Strong pricing driven primarily by strong market dynamics, and pricing focus in anticipation of further inflationary pressures
- Adjusted EBITDA margin expanded 1100 bps despite rising raw material, energy, and logistics costs

Outlook

- Improved customer demand across all products, in line with normal seasonal patterns for the business
- Focused on ability to serve all the needs of our customers through challenging supply conditions
- Well positioned to support the continued adoption of our climate friendly, low GWP Opteon™ solutions as the structural shift away from legacy refrigerants accelerates in the coming years

First Quarter 2022 Financial Summary (\$ in millions)


Quarterly Net Sales



Sales Drivers

	Yr/Yr % Δ	Q/Q % Δ
Price	40	21
Volume	1	23
Currency	(1)	0

Quarterly Adjusted EBITDA



See reconciliation of Non-GAAP measures in the Appendix. Note that, beginning in 2022, the Company changed its methodology used to allocated certain corporate function expenses to the operating segments, and as such historical Adjusted EBITDA has been recast.

Advanced Performance Materials Business Summary

First Quarter Highlights


- Record quarter – Net Sales and Adjusted EBITDA
- Net Sales increased by 16% driven by continued strength in demand and higher global average selling prices
- Price up 15% and reflective of strong demand, impact of mix shift with increasing demand from higher value applications, and actions to offset raw material inflation
- Adjusted EBITDA Margin improved 600 bps to 23% despite raw material inflation and supply chain issues

Outlook

- Customer and end market demand expected to remain strong around the world
- Anticipate value-based pricing and supply chain integration to help offset rising raw material and logistics costs over time
- Continue to optimize our product mix to target the highest value applications and most strategic customers

First Quarter 2022 Financial Summary (\$ in millions)


Quarterly Net Sales



Sales Drivers

	Yr/Yr % Δ	Q/Q % Δ
Price	15	5
Volume	3	6
Currency	(2)	0

Quarterly Adjusted EBITDA



See reconciliation of Non-GAAP measures in the Appendix. Note that, beginning in 2022, the Company changed its methodology used to allocated certain corporate function expenses to the operating segments, and as such historical Adjusted EBITDA has been recast.

Revised 2022 Guidance

Adjusted
EBITDA

\$1.475-\$1.575 Billion

Current mid-point up 12% vs. prior guidance mid-point
and 16% from 2021 results

Adjusted
EPS

\$5.04-\$5.53

Free
Cash Flow

>\$550 Million

Includes 2022 projected CAPEX of ~\$400 million

Cash to
Shareholders

The majority of our FCF

New \$750 million share repurchase authorization thru 2025

Key Factors and Assumptions¹

Low End of Range

- Further deterioration in supply chain environment
- Higher energy and raw material costs
- Prolonged China shutdowns

High End of Range

- Improved demand strength (e.g., automotive OEM production)
- Normalization of supply chain and logistics
- Earlier than anticipated ore relief

See reconciliation of Non-GAAP measures in the Appendix

¹ Subject to risks, uncertainties and assumptions, all of which are described in our public filings and safe harbor statement

Our Priorities for Creating Shareholder Value

Improve TT earnings through the cycle while growing with strategic customers

Drive secular growth in TSS and APM behind class leading products and innovative chemistry

Continue to manage and resolve legacy liabilities consistent with Chemours/DD/CTVA MOU

Return the majority of the Free Cash Flow we generate to our shareholders



Chemours™

Segment Net Sales and Adjusted EBITDA (Unaudited)

(\$ in millions)

	Three Months Ended		Three Months
	March 31,		December 31,
	2022	2021	2021
SEGMENT NET SALES			
Titanium Technologies	\$ 928	\$ 723	\$ 865
Thermal & Specialized Solutions	425	304	295
Advanced Performance Materials	385	333	346
Other Segment	26	76	69
Total Company	<u>\$ 1,764</u>	<u>\$ 1,436</u>	<u>\$ 1,575</u>
SEGMENT ADJUSTED EBITDA			
Titanium Technologies	\$ 206	\$ 166	\$ 195
Thermal & Specialized Solutions	174	90	95
Advanced Performance Materials	88	58	71
Other Segment	—	9	7
Corporate and Other	(65)	(55)	(61)
Total Company	<u>\$ 403</u>	<u>\$ 268</u>	<u>\$ 307</u>
SEGMENT ADJUSTED EBITDA MARGIN			
Titanium Technologies	22%	23%	23%
Thermal & Specialized Solutions	41%	30%	32%
Advanced Performance Materials	23%	17%	21%
Other Segment	0%	12%	10%
Corporate and Other	—	—	—
Total Company	<u>23%</u>	<u>19%</u>	<u>19%</u>

GAAP Net Income Attributable to Chemours to Adjusted Net Income, Adjusted EBITDA, and Adjusted EPS Reconciliations (Unaudited)

(\$ in millions except per share amounts)

	Three Months Ended				Three Months Ended	
	March 31,				December 31,	
	2022		2021		2021	
	\$ amounts	\$ per share*	\$ amounts	\$ per share*	\$ amounts	\$ per share*
Net income attributable to Chemours	\$ 234	\$ 1.43	\$ 96	\$ 0.57	\$ 233	\$ 1.40
Non-operating pension and other post-retirement employee benefit income	(1)	(0.01)	(1)	(0.01)	(2)	(0.01)
Exchange losses (gains), net	—	—	8	0.05	(5)	(0.03)
Restructuring, asset-related, and other charges	16	0.10	(5)	(0.03)	3	0.02
Loss on extinguishment of debt	—	—	—	—	1	0.01
Gain on sales of assets and businesses	(1)	(0.01)	—	—	(113)	(0.68)
Natural disasters and catastrophic events	—	—	16	0.09	2	0.01
Transaction costs	—	—	4	0.02	(3)	(0.02)
Qualified spend recovery	(14)	(0.09)	—	—	(8)	(0.05)
Legal and environmental charges	8	0.05	13	0.08	11	0.07
Adjustments made to income taxes	(3)	(0.02)	—	—	(3)	(0.02)
(Benefit from) provision for income taxes relating to reconciling items	—	—	(11)	(0.07)	19	0.11
Adjusted Net Income	\$ 239	\$ 1.46	\$ 120	\$ 0.71	\$ 135	\$ 0.81
Interest expense, net	41		49		43	
Depreciation and amortization	74		83		76	
All remaining provision for income taxes	49		16		53	
Adjusted EBITDA	\$ 403		\$ 268		\$ 307	
Weighted-average number of common shares outstanding - basic	159,897,673		165,652,778		162,982,696	
Weighted-average number of common shares outstanding - diluted	163,579,580		169,050,322		166,773,485	
Basic earnings per share of common stock	\$ 1.46		\$ 0.58		\$ 1.43	
Diluted earnings per share of common stock	1.43		0.57		1.40	
Adjusted basic earnings per share of common stock	1.49		0.72		0.83	
Adjusted diluted earnings per share of common stock	1.46		0.71		0.81	

* Note: \$ per share columns may not sum due to rounding.

Free Cash Flow Reconciliations (Unaudited)

(\$ in millions)

	Three Months Ended		
	March 31,		December 31,
	2022	2021	2021
Cash flows provided by operating activities	\$ 2	\$ 39	\$ 214
Less: Purchases of property, plant, and equipment	(106)	(60)	(83)
Free Cash Flows	\$ (104)	\$ (21)	\$ 131

Net Leverage Ratio (Unaudited)

(\$ in millions)

Total debt principal

Less: Cash and cash equivalents

Total debt principal, net

	As of March 31,	
	2022	2021
\$	3,748	\$ 4,027
	(1,145)	(1,008)
\$	<u>2,603</u>	<u>\$ 3,019</u>

(\$ in millions)

Adjusted EBITDA (1)

	Twelve Months Ended March 31,	
	2022	2021
\$	<u>1,448</u>	<u>\$ 890</u>

Net Leverage Ratio

1.8x

3.4x

(1) Reconciliations of net income (loss) attributable to Chemours to Adjusted EBITDA are provided on a quarterly basis. See the above table for the reconciliation of net income (loss) attributable to Chemours to Adjusted EBITDA.

Estimated GAAP Net Income Attributable to Chemours to Adjusted Net Income, Adjusted EBITDA and Adjusted EPS Reconciliation (Unaudited)

(In millions except per share amounts)

	(Estimated)	
	Year Ended December 31, 2022	
	Low	High
Net income attributable to Chemours	\$ 810	\$ 890
Restructuring, transaction, and other costs, net (1)	5	5
Adjusted Net Income	815	895
Interest expense, net	170	170
Depreciation and amortization	300	300
All remaining provision for income taxes	190	210
Adjusted EBITDA	\$ 1,475	\$ 1,575
Weighted-average number of common shares outstanding - basic (2)	158.0	158.0
Dilutive effect of the Company's employee compensation plans (3)	3.7	3.7
Weighted-average number of common shares outstanding - diluted	161.7	161.7
Basic earnings per share of common stock	\$ 5.13	\$ 5.63
Diluted earnings per share of common stock (4)	5.01	5.50
Adjusted basic earnings per share of common stock	5.16	5.66
Adjusted diluted earnings per share of common stock (4)	5.04	5.53

(1) Restructuring, transaction, and other costs, net includes the net provision for (benefit from) income taxes relating to reconciling items and adjustments made to income taxes for the removal of certain discrete income tax impacts.

(2) The Company's estimates for the weighted-average number of common shares outstanding - basic reflect results for the three months ended March 31, 2022, which are carried forward for the projection period.

(3) The Company's estimates for the dilutive effect of the Company's employee compensation plans reflect the dilutive effect for the three months ended March 31, 2022, which is carried forward for the projection period.

(4) Diluted earnings per share is calculated using net income available to common shareholders divided by diluted weighted-average common shares outstanding during each period, which includes unvested restricted shares. Diluted earnings per share considers the impact of potentially dilutive securities except in periods in which there is a loss because the inclusion of the potential common shares would have an anti-dilutive effect.

The Company's estimates reflect its current visibility and expectations based on market factors, such as currency movements, macro-economic factors, and end-market demand. Actual results could differ materially from these current estimates.

Estimated GAAP Cash Flows Provided by Operating Activities to Free Cash Flow Reconciliations (Unaudited)

(\$ in millions)

	(Estimated) Year Ended December 31, 2022
Cash provided by operating activities	\$ >950
Less: Purchases of property, plant, and equipment	~(400)
Free Cash Flows	\$ >550

The Company's estimates reflect its current visibility and expectations based on market factors, such as currency movements, macro-economic factors, and end-market demand. Actual results could differ materially from these current estimates.



Chemours™